ArticleBMC gastroenterology2018
Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.
Article in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Efficacy and safety of transjugular intrahepatic portosystemic shunt in hepatic sinusoidal obstruction syndrome: systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.Hepatology international · 2022Trial
- Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloid.BMC gastroenterology · 2026Article
- Transjugular intrahepatic portosystemic shunt improves survival in anticoagulation-resistant hepatic sinusoidal obstructive syndrome patients: A multicenter retrospective study.World journal of hepatology · 2026Article
- Hepatic sinusoidal obstruction syndrome caused by Gynura japonica once misdiagnosed as pancreatitis: a case report and review of literature.Journal of medical case reports · 2026Review
- Hepatic Sinusoidal Obstruction Syndrome Induced by Pyrrolizidine Alkaloids fromMolecules (Basel, Switzerland) · 2026Review
- Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.Archives of toxicology · 2025Review
- Radical total gastrectomy for gastric cancer complicated by hepatic sinusoidal obstruction syndrome: a case report.Frontiers in medicine · 2025Article
- Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.Archives of toxicology · 2024Article
- Hepatic Veno-Occlusive Disease and Colorectal Cancer: Expect the Unexpected.Life (Basel, Switzerland) · 2024Article
- Article
- Pyrrolizidine Alkaloids-Pros and Cons for Pharmaceutical and Medical Applications.International journal of molecular sciences · 2023Review
- Hyperoside attenuates pyrrolizidine alkaloids-induced liver injury by ameliorating TFEB-mediated mitochondrial dysfunction.Archives of pharmacal research · 2023Article
- Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.Cardiovascular and interventional radiology · 2023Article
- Serum metabolomics strategy for investigating the hepatotoxicity induced by different exposure times and doses ofRSC advances · 2023Article
- Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.Open medicine (Warsaw, Poland) · 2023Article
- Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.Journal of clinical laboratory analysis · 2022Article
- Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.Scientific reports · 2021Article
- Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.Acta pharmacologica Sinica · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic veno-occlusive disease (HVOD) caused by Gynura segetum has been increasingly reported in China in recent years. The aim of this retrospective study was to identify independent prognostic markers for survival in patients with Gynura segetum-induced HVOD and to evaluate the effect of anticoagulants and transjugular intrahepatic portosystemic shunt (TIPS) on survival rate.
methodsClinical data including symptoms, signs, imaging characteristics, laboratory test results, results of liver tissue biopsies, type of treatment during follow-up and clinical outcomes were collected. Univariate, multivariate and time-dependent Cox regression analyses were performed.
resultsSurvival rates were 91% (95% confidence interval [CI], 82-95%), 64% (95% CI, 53-69%) and 57% (95% CI, 51-65%) at 1, 3 and 60 months, respectively. Total bilirubin, albumin and hepatic encephalopathy were independent prognostic markers of survival. Anticoagulants were administered to 76% of the patients. Among 75 patients treated with anticoagulants, 49 patients (65.3%) were cured, whereas 26 patients (34.7%) died; the cure rate in anticoagulant-treated patients was higher than that of those not treated with anticoagulants (χ
conclusionsThe presence of hepatic encephalopathy, serum bilirubin and albumin levels were major prognostic factors for Gynura segetum-induced HVOD. Anticoagulation therapy significantly increased the cure rate; however, TIPS treatment did not have a beneficial effect on the cure rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.